Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …

The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …

Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …

Highlights•Multiple companies are authorized to treat COVID-19 patients with monoclonal
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …